4,803 AbbVie Inc. $ABBV Shares Bought by Phoenix Financial Ltd.

Phoenix Financial Ltd. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,244 shares of the company’s stock after purchasing an additional 4,803 shares during the quarter. Phoenix Financial Ltd.’s holdings in AbbVie were worth $13,667,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. MSH Capital Advisors LLC lifted its stake in shares of AbbVie by 0.6% in the 3rd quarter. MSH Capital Advisors LLC now owns 17,914 shares of the company’s stock valued at $4,686,000 after purchasing an additional 100 shares during the last quarter. Cornerstone Advisory LLC boosted its holdings in AbbVie by 1.0% in the third quarter. Cornerstone Advisory LLC now owns 16,358 shares of the company’s stock worth $4,279,000 after purchasing an additional 156 shares in the last quarter. Ibex Wealth Advisors increased its position in AbbVie by 0.5% during the third quarter. Ibex Wealth Advisors now owns 63,744 shares of the company’s stock worth $16,675,000 after buying an additional 320 shares during the last quarter. Condor Capital Management increased its position in AbbVie by 6.1% during the third quarter. Condor Capital Management now owns 6,145 shares of the company’s stock worth $1,608,000 after buying an additional 351 shares during the last quarter. Finally, Wellington Grp LLC raised its holdings in AbbVie by 3.4% during the third quarter. Wellington Grp LLC now owns 1,558 shares of the company’s stock valued at $408,000 after buying an additional 51 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV traded up $0.73 during midday trading on Friday, reaching $295.18. The stock had a trading volume of 3,259,920 shares, compared to its average volume of 5,279,493. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93. The firm’s fifty day simple moving average is $275.51 and its 200-day simple moving average is $240.91. The stock has a market capitalization of $521.76 billion, a P/E ratio of 50.81, a PEG ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter last year, the firm posted $1.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is presently 125.30%.

Key Headlines Impacting AbbVie

Investors following ABBV have been watching these headlines:

• Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Analysts Set New Price Targets

A number of analysts have weighed in on ABBV shares. Barclays boosted their price target on AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Guggenheim boosted their target price on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $297.46.

Insider Buying and Selling at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.